ERBB2 and breast carcinoma: This strategy was based on a clear synergy between anti-HER2 therapy and CDK4/6 inhibitors in HER2+ breast cancer cell lines (18, 19) and the demonstration in transgenic mice that the activation of cyclin D1–CDK4/6 was involved in mediating resistance to anti-HER2 therapy (20).